Cannabinoid Receptor Antagonists

Compounds that inhibit or block the activity of CANNABINOID RECEPTORS.

Also Known As:

Cannabinoid Antagonists; Cannabinoid Blockers; Cannabinoid Receptor Blockers; Antagonist, Cannabinoid; Antagonist, Cannabinoid Receptor; Antagonists, Cannabinoid; Antagonists, Cannabinoid Receptor; Blocker, Cannabinoid; Blocker, Cannabinoid Receptor; Blockers, Cannabinoid; Blockers, Cannabinoid Receptor; Receptor Antagonist, Cannabinoid; Receptor Antagonists, Cannabinoid; Receptor Blocker, Cannabinoid; Receptor Blockers, Cannabinoid; Cannabinoid Antagonist; Cannabinoid Blocker; Cannabinoid Receptor Antagonist; Cannabinoid Receptor Blocker

Networked: 101 relevant articles (6 outcomes, 13 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Chemical Actions and Uses
- Pharmacologic Actions: 160
  - Molecular Mechanisms of Pharmacological Action: 24
    - Neurotransmitter Agents: 13181
      - Cannabinoid Receptor Modulators: 2
        Cannabinoid Receptor Antagonists: 101
  - Physiological Effects of Drugs: 1
    - Hormones, Hormone Substitutes, and Hormone Antagonists
      - Hormones: 80400
        Cannabinoid Receptor Modulators: 2
        Cannabinoid Receptor Antagonists: 101

Experts

1.	Lichtman, A H: 4 articles (08/2008 - 05/2001)
2.	Martin, B R: 4 articles (08/2008 - 05/2001)
3.	Bays, Harold: 3 articles (08/2007 - 03/2006)
4.	van Rijn, Clementina M: 2 articles (01/2017 - 10/2011)
5.	Heinz, Andreas: 2 articles (09/2016 - 10/2007)
6.	Welch, Sandra P: 2 articles (08/2013 - 09/2006)
7.	Rodríguez de Fonseca, Fernando: 2 articles (04/2012 - 01/2008)
8.	Lutz, B: 2 articles (10/2010 - 03/2003)
9.	Zimmer, Andreas: 2 articles (12/2008 - 06/2007)
10.	Idris, Aymen I: 2 articles (11/2008 - 07/2005)

Related Diseases

1.	Obesity 01/01/2020 - "Cannabinoid receptor antagonists have been suggested as a novel treatment for obesity and diabetes. " 04/01/2012 - "In this study we analysed the effects of LH-21, a peripherally acting neutral cannabinoid receptor antagonist with poor brain penetration, in an animal model of diet-induced obesity. " 12/01/2016 - "BMS-725519, BMS-811064, and BMS-812204 are potent and selective central cannabinoid receptor antagonists that have been investigated for the treatment of human obesity. " 10/01/2010 - "Peripherally active, cannabinoid receptor antagonists with limited brain penetration may be useful agents for the treatment of obesity and its complications." 06/01/2004 - "We have recently seen a 46-year-old woman who developed MS after starting treatment with a cannabinoid receptor antagonist for obesity. "
2.	Alcoholism (Alcohol Abuse) 01/01/2016 - "In addition, some observations indicate that cannabinoid receptor antagonists may be useful for the treatment of alcohol dependence and addiction, which is a major health concern worldwide. " 06/01/2008 - "Taking the substantial numbers of animal studies suggesting a possible role of CB1 antagonists for the treatment of alcohol dependence into account, it seems worthwhile to further test cannabinoid blockers in the treatment of alcoholism."
3.	Parkinson Disease (Parkinson's Disease) 06/01/2001 - "The data support the idea that cannabinoid receptor antagonists may provide a useful treatment for the symptoms of Parkinson's disease." 06/01/2001 - "We further investigated the therapeutic potential of cannabinoid antagonists in a primate model of Parkinson's disease. " 11/05/2009 - "Thus, not only is a cannabinoid antagonist monotherapeutic in this animal model of Parkinson's disease, but it also enhances the therapeutic effect of a moderate, but not a high, dose of l-DOPA." 05/01/2004 - "Neurokinin B, neurotensin, and cannabinoid receptor antagonists and Parkinson disease." 01/01/2007 - "Numerous diseases, such as anorexia, emesis, pain, inflammation, multiple sclerosis, neurodegenerative disorders (Parkinson's disease, Huntington's disease, Tourette's syndrome, Alzheimer's disease), epilepsy, glaucoma, osteoporosis, schizophrenia, cardiovascular disorders, cancer, obesity, and metabolic syndrome-related disorders, to name just a few, are being treated or have the potential to be treated by cannabinoid agonists/antagonists/cannabinoid-related compounds. "
4.	Parkinsonian Disorders (Parkinsonism) 10/01/1999 - "It can be speculated that cannabinoid antagonists might be useful in the treatment of chorea in Huntington s disease and hypokinetic parkinsonian syndromes." 06/01/2001 - "In view of the psychomotor slowing induced by cannabinoid agonists, we investigated the therapeutic potential of the cannabinoid receptor antagonist SR141716A in an early and advanced stage of 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine-induced parkinsonism. "
5.	Huntington Disease (Huntington's Disease) 10/01/1999 - "It can be speculated that cannabinoid antagonists might be useful in the treatment of chorea in Huntington s disease and hypokinetic parkinsonian syndromes." 01/01/2007 - "Numerous diseases, such as anorexia, emesis, pain, inflammation, multiple sclerosis, neurodegenerative disorders (Parkinson's disease, Huntington's disease, Tourette's syndrome, Alzheimer's disease), epilepsy, glaucoma, osteoporosis, schizophrenia, cardiovascular disorders, cancer, obesity, and metabolic syndrome-related disorders, to name just a few, are being treated or have the potential to be treated by cannabinoid agonists/antagonists/cannabinoid-related compounds. "

Related Drugs and Biologics

1.	Cannabinoid Receptor Agonists
2.	Morphine (MS Contin)
3.	Rimonabant
4.	Cannabinoids
5.	Endocannabinoids
6.	Analgesics (Analgesic Drugs)
7.	anandamide (arachidonylethanolamide)
8.	Cannabinoid Receptors (Cannabinoid Receptor)
9.	Naloxone (Narcan)
10.	CB1 Cannabinoid Receptor (CB1 Receptor)

Related Therapies and Procedures

1.	Therapeutics
2.	Analgesia
3.	Ovariectomy (Oophorectomy)
4.	Investigational Therapies (Experimental Therapy)
5.	Punctures